Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Watson, Katrina L ^a   Moorehead, Roger A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; CYTOKERATIN; ISOPROTEIN; PROTEIN KINASE B; PROTEIN KINASE B BETA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; AKT1 PROTEIN, MOUSE; AKT2 PROTEIN, MOUSE;

ABLATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CARCINOGENESIS; CELL STRUCTURE; CROSS BREEDING; DISEASE ACTIVITY; ENZYME PHOSPHORYLATION; GROWTH RATE; LUNG METASTASIS; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR ONSET; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1;

EID: 84881039310     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-375     Document Type: Article

References (49)

1. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003, 107:873-877. 10.1002/ijc.11487, 14601044.
2. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003, 195:127-137. 10.1016/S0304-3835(03)00159-9, 12767520.
3. Furstenberger G, Morant R, Senn HJ. Insulin-like growth factors and breast cancer. Onkologie 2003, 26:290-294. 10.1159/000071627, 12845216.
4. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998, 47:255-267. 10.1023/A:1005907101686, 9516080.
5. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mam Gland Biol Neoplasia 2000, 5:95-105.
6. Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Matsubara O, et al. Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci 2006, 97:597-604. 10.1111/j.1349-7006.2006.00228.x, 16827799.
7. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 2004, 35:1537-1542. 10.1016/j.humpath.2004.09.005, 15619214.
8. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004, 64:286-291. 10.1158/0008-5472.CAN-03-1242, 14729636.
9. Koda M, Przystupa W, Jarzabek K, Wincewicz A, Kanczuga-Koda L, Tomaszewski J, et al. Expression of insulin-like growth factor-I receptor, estrogen receptor alpha, Bcl-2 and Bax proteins in human breast cancer. Oncol Rep 2005, 14:93-98.
10. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 1988, 48:6429-6433.
11. Koda M, Sulkowski S, Garofalo C, Kanczuga-Koda L, Sulkowska M, Surmacz E. Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta. Horm Metab Res 2003, 35:794-801.
12. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007, 67:11565-11575. 10.1158/0008-5472.CAN-07-2536, 18089785.
13. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A 2009, 106:2359-2364. 10.1073/pnas.0810221106, 2650161, 19174523.
14. Lerma E, Peiro G, Ramon T, Fernandez S, Martinez D, Pons C, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2007, 20:1200-1207. 10.1038/modpathol.3800961, 17885672.
15. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005, 65:3781-3787. 10.1158/0008-5472.CAN-04-4602, 15867374.
16. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26:1636-1644. 10.1038/sj.onc.1209955, 16953219.
17. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464. 10.1038/sj.onc.1209085, 16288292.
18. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001, 26:657-664. 10.1016/S0968-0004(01)01958-2, 11701324.
19. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008, 23:1-9.
20. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998, 335(Pt 1):1-13. 1219745, 9742206.
21. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
22. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 1991, 88:4171-4175. 10.1073/pnas.88.10.4171, 51620, 1851997.
23. Jones PF, Jakubowicz T, Hemmings BA. Molecular cloning of a second form of rac protein kinase. Cell Regul 1991, 2:1001-1009. 361900, 1801921.
24. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 1995, 216:526-534. 10.1006/bbrc.1995.2654, 7488143.
25. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999, 274:9133-9136. 10.1074/jbc.274.14.9133, 10092583.
26. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001, 276:38349-38352. 10.1074/jbc.C100462200, 11533044.
27. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001, 292:1728-1731. 10.1126/science.292.5522.1728, 11387480.
28. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 2003, 112:197-208. 164287, 12843127.
29. Yang W, Ju JH, Lee KM, Shin I. Akt isoform-specific inhibition of MDA-MB-231 cell proliferation. Cell Signal 2011, 23:19-26. 10.1016/j.cellsig.2010.07.016, 20688159.
30. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005, 171:1023-1034. 10.1083/jcb.200505087, 2171329, 16365168.
31. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009, 69:5057-5064.
32. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007, 67:167-177. 10.1158/0008-5472.CAN-06-3782, 17210696.
33. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007, 67:3970-3975. 10.1158/0008-5472.CAN-06-3822, 17440113.
34. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene 2009, 13:407-413.
35. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van RF, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003, 63:2172-2178.
36. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007, 67:1979-1987. 10.1158/0008-5472.CAN-06-1479, 17332325.
37. Franks SE, Campbell CI, Barnett EF, Siwicky MD, Livingstone J, Cory S, et al. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics while IGF-IR independent mammary tumors express a claudin-low gene signature. Oncogene 2011, in press.
38. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
39. Serra V, Scaltriti M, Prudkin L, Eichorn PJ, Ibrahim YH, Chandarlapaty S, Marman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557. 10.1038/onc.2010.626, 3107390,3107390, 21278786.
40. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006, 207:420-427. 10.1002/jcp.20588, 16419029.
41. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 1995, 26:678-690. 10.1016/0272-6386(95)90610-X, 7573028.
42. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279. 10.1016/j.cell.2004.07.011, 15294153.
43. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
44. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011, 10:1563-1570. 10.4161/cc.10.10.15703, 21502814.
45. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003, 5:101-106. 10.1186/bcr578, 154156, 12631389.
46. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev 2011, 38:689-697.
47. Dhasarathy A, Phadke D, Mav D, Shah RR, Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS One 2011, 6:e26514. 10.1371/journal.pone.0026514, 3197668, 22028892.
48. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res 2011, 9:1644-1657. 10.1158/1541-7786.MCR-11-0371, 22006115.
49. Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 2011, 13:211. 10.1186/bcr2876, 3218933, 21672282.